By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Acorda Therapeutics 

15 Skyline Drive

Hawthorne  New York  10532  U.S.A.
Phone: 914-347-4300 Fax: 914-347-4560

Acorda Therapeutics is a privately held biotechnology company developing therapies for spinal cord injury (SCI) and related neurological conditions, including multiple sclerosis (MS). The Company's lead product, Fampridine-SR, is in Phase 3 clinical trials for chronic SCI and Phase 2 for MS.

Fampridine-SR acts to combat the effects of demyelination in the spinal cord. Myelin is the insulating sheath around nerve processes; when it is damaged due to trauma or disease, electrical impulses from the brain cannot be conducted past the demyelinated area. Fampridine-SR chemically blocks the exposed voltage-gated potassium channels, allowing the impulse from the brain to be conducted more normally past the area of damage. Fampridine is being studied in Phase 3 clinical trials to evaluate its efficacy in reducing spasticity in people with chronic spinal cord injury. Secondary endpoints in the study include evaluating its effect on bladder, bowel, and sexual function. The Company is also conducting a 152 patient, late Phase 2 clinical study in MS to evaluate Fampridine-SR's efficacy in walking speed and muscle strength.

Acorda's technology platform also includes two remyelinating agents in preclinical development for MS. The first is M1, a class of human monoclonal antibodies that have been shown to remyelinate the central nervous system in animal models, and the second is GGF2, a product of the neuregulin 1 gene. Preclinical studies have shown that GGF2 can stimulate the cell growth necessary to protect and regenerate damaged myelin. Additionally, Acorda is developing protein- and stem cell-based technologies for regeneration and repair of the spinal cord and brain.

In 2002, Acorda was the recipient of the National Spinal Cord Injury Association's L. W. Freeman Award for scientific research.

Key Management:

Ron Cohen, M.D., President and CEO
Andrew R. Blight, Ph.D., Executive Vice President, Research & Development
Mary Fisher, Vice President, Marketing and Strategic Planning
Elliott A. Gruskin, Ph.D., Vice President, Research & Development
Mitchell Katz, Ph.D., Vice President, Clinical Programs
David Lawrence, Vice President, Finance
Mark R. E. Pinney, C.F.A., Chief Financial Officer and Director
Harold Safferstein, Ph.D., J.D., Vice President, Business Development

Last Updated: 05-09-03

Key Statistics

Ownership: Public

Web Site: Acorda
Symbol: ACOR




Athersys  A functional genomics collaboration focused on the discovery of validated drug targets to treat certain central nervous system disorders, including spinal cord injuries and multiple sclerosis. Athersys and Acorda will jointly own therapeutic products or validated targets identified and developed through the collaboration.


Company News
Acorda (ACOR) Adopts Shareholder Rights Plan 9/1/2017 6:43:13 AM
Struggling Acorda (ACOR) Adopts Plan To Fend Off Takeover Attempts 9/1/2017 6:38:03 AM
Acorda (ACOR) Plunges After the FDA Rejects Marketing App for Parkinson's Disease Drug 8/29/2017 5:55:20 AM
Acorda (ACOR) Investor Urges for Company to Explore Sale 8/7/2017 7:17:09 AM
Acorda (ACOR) Provides Financial And Pipeline Update For Second Quarter 2017 7/27/2017 6:58:07 AM
Acorda (ACOR) Second Quarter 2017 Update Webcast/Conference Call Scheduled For July 27, 2017 7/13/2017 6:30:02 AM
Acorda (ACOR) Submits New Drug Application To U.S. FDA For INBRIJATM (CVT-301, Levodopa Inhalation Powder) 6/30/2017 6:40:13 AM
Acorda (ACOR) Release: CVT-301 Phase III Data Showed Significantly Improved Motor Function During OFF Periods In Parkinson’s Disease 6/6/2017 8:06:55 AM
Acorda (ACOR) Presenting New Tozadenant Data At 2017 MDS Congress 6/6/2017 7:20:00 AM
Acorda (ACOR) Jumps as Parkinson’s Drug Performs Well in Late-Stage Study 6/6/2017 6:06:59 AM